Ann: Opthea to Host Key Opinion Leader Event on April 3, 2024, page-7

Bullish; also, $1.20 seems very possible, but I prefer to imagine a range of possibilites from 80 cents through to 1.50 in 2024.

As others at HC here have warned, there could/would be the need for yet another capital raise sic before we get a final read of results. Let's hope by that time, if it happens, even a 20% CR decline will be well above today's $0.72 cents. Guesses Q2, Q3, Q4 this year for CR, if there is going to be one in 2024?

Is OPT Sozinibercept an all-or-nothing situation?
What do others think the future may hold if the results are not what we hope for? For example, if the Stage III trials achieve a positive but not statistically significant result for Sozinibercept—hypothetically, "The preliminary findings from the clinical trial indicate potential positive effects; however, the results have not achieved statistical significance to meet FDA standards for conclusive evidence of efficacy"—is OPT a 0 cent stock, or could there be some options?

Personally, I would greatly increase my holding if zero were not a very real possibility. Happy (but not happy) to take a 50% loss eg 30cents , but going to zero would be nasty and thus mitigates the buy button finger.